Header Logo

Connection

Arthur Krieg to Neoplasms

This is a "connection" page, showing publications Arthur Krieg has written about Neoplasms.
Connection Strength

1.225
  1. Krieg AM. New insights into the role of IFN-a/? and TLR7/8/9 in cancer immunotherapy and systemic autoimmunity. J Immunother Cancer. 2025 Sep 18; 13(9).
    View in: PubMed
    Score: 0.459
  2. Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD, Krieg AM. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother. 2009 Apr; 58(4):615-28.
    View in: PubMed
    Score: 0.141
  3. Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008 Jan 07; 27(2):161-7.
    View in: PubMed
    Score: 0.135
  4. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007 May; 117(5):1184-94.
    View in: PubMed
    Score: 0.128
  5. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep. 2004 Mar; 6(2):88-95.
    View in: PubMed
    Score: 0.103
  6. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 2012 Apr; 22(2):77-89.
    View in: PubMed
    Score: 0.045
  7. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. Cancer and inflammation: promise for biologic therapy. J Immunother. 2010 May; 33(4):335-51.
    View in: PubMed
    Score: 0.039
  8. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009 Mar 28; 61(3):195-204.
    View in: PubMed
    Score: 0.036
  9. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun; 5(6):471-84.
    View in: PubMed
    Score: 0.030
  10. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res. 2005 Jan 01; 11(1):361-9.
    View in: PubMed
    Score: 0.027
  11. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20:709-60.
    View in: PubMed
    Score: 0.022
  12. Krieg AM. From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev. 2001 Jun; 11(3):181-8.
    View in: PubMed
    Score: 0.021
  13. Krieg AM. The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb; 12(1):35-43.
    View in: PubMed
    Score: 0.019
  14. Krieg AM. CpG oligonucleotides as immune adjuvants. Ernst Schering Res Found Workshop. 2000; (30):105-18.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.